<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210111050010N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-06</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The Effects  of Family-Based Dignity Intervention and Expressive Writing   on Grief of Family Caregivers of Clients With Cancer</public_title>
      <acronym></acronym>
      <scientific_title>The Effects  of Family-Based Dignity Intervention and Expressive Writing  Intervention on Grief of Family Caregivers of Clients With Cancer: An Embedded Mixed Methods Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53685</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: After recruiting 200 family caregivers of dying cancer patients according to inclusion criteria, they will be randomly assigned to one of the four groups: family-based dignity intervention (group 1), expressive writing intervention (group 2), combined family-based dignity intervention and expressive writing (group 3), and controls (group 4). Allocation concealment will be done using the blocked randomization method. For this, we will use six blocks with the sizes of 4 (A: group 1, B: group 2, C: group 3, and D: group 4) that the order of the letters in the six block will be different (e.g. ABCD, ACDB, and etc.). Then, a code ranging between 1 and 6 will be assigned to each block. For allocating each four caregivers, at first, we will randomly select one of the six blocks using a 6-sided dice, and then, caregivers will be assigned to the four intervention group according to the order of letters in the selected block. Until the all groups become complete, the random allocation will continue.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Our community for study is healthy caregivers.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group :In Family-based dignity  intervention  caregivers will received family-based dignity intervention according to Ho et al. protocol as well as routine interventions including family counseling and hope and meaning therapy. For the dignity intervention, a 60-90-minute intervention interview session will take place for each caregiver in a private room in the palliative care center. In this session, caregivers will be asked to answer 12 open-ended questions related to the Ho et al. protocol. The questions focus on eliciting caregivers’ experiences of living with a cancer patient before and after the diagnosis of cancer. Also, these questions will help caregivers to review the beautiful memories of living with a cancer patient and express their hopes, wishes, and desired expectations. The responses to these questions will be audio-recorded and then, will be transcribed verbatim in a manuscript for each caregiver. The manuscript will be checked with caregivers and, if needed, corrections will be done. A copy of the manuscript will be delivered to caregivers. One week after the baseline assessment, anticipatory grief will be assessed (one week after T1 or T2). Two weeks after the baseline assessment, the anticipatory grief will be re-assessed. Intervention 2: The Second intervention group:  After assessing baseline anticipatory grief, caregivers will be asked to write about their positive and negative experiences during caregiving cancer patients. This intervention will be done based on the Pennebaker method. Before the intervention, caregivers will be instructed by a trained researcher in order to do this writing. The researcher will receive training on expressive writing by participating in a writing art workshop. Caregivers in this group will be asked to write about a prompt, and they will be instructed to ‘‘really let go and explore their very deepest emotions and thoughts”. They will be also told to write about either negative or positive family memories and describe their experiences of caregiving in the present and past time. This writing should be done three times (in a week) lasting 20 minutes. In that week, the researcher will remind the writing process using a phone call. They are also assured that they do not need to worry about sentence structure or grammar when writing. After one week opportunity for expressive writing, the manuscript of caregivers will be received. After the expressive writing, anticipatory grief will be assessed (one week after T1). Also, we will assess anticipatory grief two weeks after the baseline assessment (two weeks after T1). Intervention 3: The third intervention group: caregivers will received both interventions mentioned in the previous paragraphs. At first, a 60-90-minute intervention interview session about family-based dignity intervention will take place for each caregiver in a private room in the palliative care center. After the interview, caregivers will be asked to write about their positive and negative experiences during caregiving cancer patients three times, lasting 20 minutes, in a week. After one week opportunity for expressive writing, the manuscript of caregivers will be received. One week after the expressive writing and dignity intervention, anticipatory grief will be assessed (one week after T1). Also, we will assess anticipatory grief two weeks after the baseline assessment (two weeks after T1). Intervention 4: Control group : Caregivers will be received family counseling and hope and meaning therapy. The other 3 group will also receive the same intervention administered for group 4. Anticipatory grief will be assessed in the same times as mentioned for other intervention groups. In total, the duration of this study from participants entry to the last assessment will last four weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
study outcomes by maintaining anonymity of participants

When:
starting information accessibility from 2022

To whom:
university researchers and healthcare workers and people

Conditions:
Using the results of the study is permitted by regard the right of citations .

Where to obtain:
To chief author in Iran  faculty of nursing and midwifery

How to obtain:
Communicate with writers through email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoud Rezaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Rashid Yasemi st., Valiasr St., Tehran, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 4365 1000</telephone>
        <email>Masoud.rezaei68@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoud Rezaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Rashid Yasemi st., Valiasr St., Tehran, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 4365 1000</telephone>
        <email>Masoud.rezaei@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>having over 18 year 's old
Not having of known psychological disorders in family caregivers of cancer patients
Not having a history of death in close relatives last 6 month</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Caregivers who have a history of psychological disorders
Those who have a history of death among their first-degree relatives.
Those who have an experience of psychological interventions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group :In Family-based dignity  intervention  caregivers will received family-based dignity intervention according to Ho et al. protocol as well as routine interventions including family counseling and hope and meaning therapy. For the dignity intervention, a 60-90-minute intervention interview session will take place for each caregiver in a private room in the palliative care center. In this session, caregivers will be asked to answer 12 open-ended questions related to the Ho et al. protocol. The questions focus on eliciting caregivers’ experiences of living with a cancer patient before and after the diagnosis of cancer. Also, these questions will help caregivers to review the beautiful memories of living with a cancer patient and express their hopes, wishes, and desired expectations. The responses to these questions will be audio-recorded and then, will be transcribed verbatim in a manuscript for each caregiver. The manuscript will be checked with caregivers and, if needed, corrections will be done. A copy of the manuscript will be delivered to caregivers. One week after the baseline assessment, anticipatory grief will be assessed (one week after T1 or T2). Two weeks after the baseline assessment, the anticipatory grief will be re-assessed.</i_keyword>
      <i_keyword>The Second intervention group:  After assessing baseline anticipatory grief, caregivers will be asked to write about their positive and negative experiences during caregiving cancer patients. This intervention will be done based on the Pennebaker method. Before the intervention, caregivers will be instructed by a trained researcher in order to do this writing. The researcher will receive training on expressive writing by participating in a writing art workshop. Caregivers in this group will be asked to write about a prompt, and they will be instructed to ‘‘really let go and explore their very deepest emotions and thoughts”. They will be also told to write about either negative or positive family memories and describe their experiences of caregiving in the present and past time. This writing should be done three times (in a week) lasting 20 minutes. In that week, the researcher will remind the writing process using a phone call. They are also assured that they do not need to worry about sentence structure or grammar when writing. After one week opportunity for expressive writing, the manuscript of caregivers will be received. After the expressive writing, anticipatory grief will be assessed (one week after T1). Also, we will assess anticipatory grief two weeks after the baseline assessment (two weeks after T1).</i_keyword>
      <i_keyword>The third intervention group: caregivers will received both interventions mentioned in the previous paragraphs. At first, a 60-90-minute intervention interview session about family-based dignity intervention will take place for each caregiver in a private room in the palliative care center. After the interview, caregivers will be asked to write about their positive and negative experiences during caregiving cancer patients three times, lasting 20 minutes, in a week. After one week opportunity for expressive writing, the manuscript of caregivers will be received. One week after the expressive writing and dignity intervention, anticipatory grief will be assessed (one week after T1). Also, we will assess anticipatory grief two weeks after the baseline assessment (two weeks after T1).</i_keyword>
      <i_keyword>Control group : Caregivers will be received family counseling and hope and meaning therapy. The other 3 group will also receive the same intervention administered for group 4. Anticipatory grief will be assessed in the same times as mentioned for other intervention groups. In total, the duration of this study from participants entry to the last assessment will last four weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anticipatory Grief. Timepoint: pretest-  one week and two week after intervention. Method of measurement: Licertic scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-11</approval_date>
        <contact_name>Iran National Committee for Ethics in Biomedical Research</contact_name>
        <contact_address>School of Nursing &amp; Midwifery, Rashid Yasemi st., Valiasr St., Tehran, 1996713883, IRAN Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
